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Dexamethasone minimizes the risk of cranial
nerve injury during CEA
Guido Regina, MD,a Domenico Angiletta, MD,a Giovanni Impedovo, MD,a Giovanni De Robertis, MD,a
Marialuisa Fiorella, MD,b and Maria Rosaria Carratu’, MD,c Bari, Italy
Objective: The incidence of cranial and cervical nerve injury during carotid endarterectomy (CEA) ranges from less than
7.6% to more than 50%. Lesions are mainly due to surgical maneuvers such as traction, compression, tissue electrocoag-
ulation, clamping, and extensive dissections. The use of dexamethasone (DEX) and its beneficial effects in spinal cord
injuries have already been described. We investigated whether DEX could also be beneficial to minimize the incidence of
cranial and cervical nerve injury during CEA.
Purpose: To evaluate whether dexamethasone is able to reduce the incidence of cranial nerve injuries.
Materials and Methods: From March 1999 through April 2006, 1126 patients undergoing CEA because of high-grade
carotid stenosis were enrolled and randomized by predetermined randomization tables into two groups. The first group,
“A”, included 586 patients that all received an intravenous administration of dexamethasone following a therapeutic
scheme. The second group, “B”, included 540 control subjects that received the standard pre- and postoperative therapy.
All patients were submitted to a deep cervical plexus block, eversion carotid endarterectomy, and selective shunting.
Three days after the operation, an independent neurologist and otorhinolaryngologist evaluated the presence of
cranial nerve deficits. All patients (group A and group B) showing nerve injuries continued the treatment (8 mg of
dexamethasone once in the morning) for 7 days and were re-evaluated after 2 weeks, 30 days, and every 3 months for 1
year. Recovery time took from 2 weeks to 12 months, with a mean time of 3.6 months. The 2 test was used to compare
the two groups and to check for statistical significance.
Results: The incidence of cranial nerve dysfunction was higher in group B and the statistical analysis showed a significant
effect of dexamethasone in preventing the neurological damage (P  .0081). The incidence of temporary lesions was
lower in group A and the 2 test yielded a P value of .006. No statistically significant differences were found when
comparing the effect of dexamethasone in men and women. In addition, dexamethasone had no statistically significant
effect on the incidence of permanent cranial nerve injuries. Finally, no adverse effect related to the administration of
dexamethasone was observed.
Conclusion: Perioperative administration of dexamethasone is effective in minimizing the incidence of temporary cranial
nerve injuries during CEA. (J Vasc Surg 2009;49:99-103.)The reported incidence of cranial nerve injury due to
carotid endarterectomy (CEA) ranges from 7.6% to 50%,1-6
depending on the methods used to detect such injuries.
Although most cranial nerve deficits are transient, severe
permanent dysfunction and even cranial nerve injury re-
lated deaths have been reported. Carotid artery stenting
avoids this complication but not all patients can be treated
by endovascular surgery. Current strategies for preventing
cranial nerve injuries focus on a thorough understanding of
the anatomical relationships, identification of nerves, care-
ful handling of tissues, sharp dissection of the arterial wall,
gentle retraction, and optimal hemostasis.7 The potential
for prevention or treatment of this common complication
with pharmacological therapy has not yet been systemati-
cally evaluated.
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Vascular Surgery.doi:10.1016/j.jvs.2008.08.049The beneficial effects of dexamethasone (DEX) therapy
in spinal cord injuries are well documented.8-11 DEX has a
pharmacological profile and a chemical structure similar to
methylprednisolone (MPD), another glucocorticoid used
for human therapy of spinal cord injury (SCI).12,13 Like
MPD, DEX therapy attenuates the expression of pro-
inflammatory cytokines, such as TNF- and IL-1, that are
increased at the injury site within the first few hours after
SCI to regulate the subsequent cellular events.14-16 These
two cytokines also have an important function in the induc-
tion of inducible nitric oxide synthase leading to nitric
oxide/peroxynitrite production and apoptotic cell death.17
Indeed, apoptosis can be detected in the peri-lesion area
after SCI. There is evidence that in addition to nitric oxide,
either oxidative or nitrosative stress are involved in the second-
ary neuronal damage found in SCI.18 Therefore, inhibition
of free radical-mediated cell injury may be another benefi-
cial effect of corticosteroid therapy. In the rat brain, DEX
induces the expression of neurotrophic factors, such as
nerve growth factor, basic fibroblast growth factor (FGF2),
and brain-derived neurotrophic factors that are known to
prevent cell death due to secondary injury.19,20 Moreover,
it has been demonstrated that FGF2 increases long-term
survival of spinal motor neurons and improves respiratory
function after experimental spinal cord injury.21 Therefore,
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contribute to enhanced regenerative responses and func-
tional recovery after SCI. In 1995, Lan Yao showed that
DEX was able to facilitate the repair of the hypoglossal
nerve in rats, but no studies proving its efficacy in human
cranial nerve lesions have been published.22 In 1999, we
initiated a prospective randomized placebo-controlled
trial to evaluate the efficacy of DEX in the prevention and
treatment of carotid endarterectomy-related cranial
nerve injuries.
MATERIAL AND METHODS
From March 1999 through April 2006, 1126 patients
undergoing CEA because of high-grade carotid stenosis
(70% luminal narrowing) were enrolled. Informed con-
sent was obtained from all subjects. They were randomized
by predetermined randomization tables into two groups
and were treated by a single surgical and anesthesia team.
Patients with restenosis or “hostile neck” (prior surgery,
radiation) were excluded. The first group (A) included 586
patients (302 men and 284 women, aged 63-76). In
addition to standard surgical and anesthesia manage-
ment, all group A subjects received 8 mg of dexametha-
sone 1 hour before the operation, at 6 and 12 hours after
the operation, every 12 hours on postoperative day #1,
and once in the morning of postoperative day #2. The
second group (B) included 540 control subjects (316
men and 224 women 62-76 years), who received the
same standard pre- and postoperative therapy, including
antibiotic prophylaxis and antiplatelet agents, but did
not receive pre-treatment with DEX. In order to dem-
onstrate a difference in cranial nerve injury of 4% be-
tween groups A and B with significance of 0.05 and
power0.8, we calculated a necessary sample size of 650
subjects in each group. This estimated sample size antic-
ipated a loss to follow-up rate of 10%.
All patients were treated with deep cervical plexus
block and eversion carotid endarterectomy with selective
shunting. Three days after the operation a neurologist
and an otorhinolaryngologist evaluated the presence of
cranial nerve deficits by clinical examination and video-
laryngoscopy. These physicians were blinded as to the
group assignment of the patients. The nerve injuries
were defined as temporary if the manifestations resolved
within 12 months.
All patients (group A and group B) with nerve injuries
received corticosteroid treatment (8 mg of dexamethasone
daily) for 7 days following injury detection and were re-
evaluated after 2 weeks, 30 days, and every 3 months for 1
year.
The 2 test was used for statistical analysis. Statistical
significance was inferred for P  .05.
RESULTS
In Group A, 44% of the patients were asymptomatic,
29% had experienced one or more transient ischemic at-
tacks (TIAs), 14% had non hemispheric symptoms, and
13% had suffered a major stroke. In Group B, 47.5% of thepatients were asymptomatic, 27% had experienced one or
more TIAs, 14% had non hemispheric symptoms, and
11.5% had suffered a major stroke (Table I).
In group A, 19 (3.2%) patients suffered cranial nerve
injury, temporary in 2.3% and permanent in 0.9%. In group
B, 37 (6.8%) patients experienced nerve dysfunction, tem-
porary in 5.7% and permanent in 1.1% (Table II). For those
with temporary lesions, recovery time took from 2 weeks to
10months, with amean time of 3.6months. The difference
in the incidence of cranial nerve injury in group A was
statistically significantly less than that of group B (P 
.0081) suggesting a beneficial role for dexamethasone. Of
note is that the difference was seen only in the incidence of
temporary injuries (P  .006) (Table III). There was no
difference between the groups in the incidence of perma-
nent injuries (0.9% vs 1.1%). Moreover, there were no
statistically significant gender influences on the incidence of
cranial nerve injury or on the effect of DEX treatment. No
postoperative infections or other adverse effects related to
administration of dexamethasone were observed.
The size and gender discrepancy between the two
groups is due to loss of patients during follow-up (10%), to
exclusion of patients due to perioperative stroke or death
(2%), and to exclusions for other deaths within the follow-up
period (0.9%) (Table IV).
DISCUSSION
The reported incidence of carotid endarterectomy-
associated cranial nerve injury ranges from less than 7.6% to
more than 50%, depending on whether the study was
conducted prospectively or retrospectively and depending
on the sensitivity of the methods employed for detecting
cranial nerve injuries. Avoiding morbidity related to cranial
nerve injuries has taken on even greater importance since
carotid stenting now vies with endarterectomy for position
as the default treatment for patients with severe carotid
Table I. Patients’ demographics
Patients
demographics Group A Group B P value
Patients 586 540
Gender
Male 302 316
Female 284 224
Age (years) 63-76 62-76
Hypertension 428 (73%) 410 (76%) .2977
Diabetes mellitus 143 (24%) 115 (22%) .2428
Smoking habit 174 (30%) 169 (31%) .6036
Hyperlipidemia 227 (39%) 215 (40%) .7574
History of MI 115 (20%) 102 (19%) .8126
Symptoms
TIA 170 (29%) 146 (27%) .5030
nHS 82 (14%) 76 (14%) .9689
Stroke 76 (13%) 62 (11.5%) .5031
Asymptomatic 257 (44%) 257 (47.5%) .2311
MI, Myocardial infarction; TIA, transient ischemic attack; nHS, non hemi-
spheric symptoms (dizziness, syncope, headache, confusion).atherosclerosis.
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neck is both complex and variable. Furthermore, the
ultrastructural characteristics of both the nerve fascicles
and the epineural tissues determine their tolerance for
mechanical and thermal trauma. The nerve trunks’ elas-
ticity and tensile strength, together with their ability to
adapt to traction and deformation, depend on the fascicular
tissues, while the epineurium has a protective role against
compression forces.
Most cranial nerve injuries are caused by traction, com-
pression, electrocautery, inadvertent clamping, ligatures, or
partial to total transections. Such events can result in the
full range of peripheral nerve injuries including:23
(1) Conduction loss without structural interruption.
(2) Axonal interruption with endoneural tube integrity.
(3) Axonal and endoneural tube disruption without
epineural or perineural damage.
(4) Loss of continuity of the perineurium, distal Wallerian
degeneration.
(5) Transection (loss of continuity of the epineurium, dis-
tal Wallerian degeneration).
Traction, compression, and electrocoagulation are
mainly responsible for lesion types 1, 2, and 3, whereas
ligature and complete transection are responsible for lesion
types 4 and 5.
The perioperative inflammatory response related to
operative trauma may play a role in modulating lesion types
1, 2, and 3 as well as those nerve injuries related to cervical
plexus block and postoperative scarring. In view of the
possibility that inflammation plays a role in perioperative
cranial nerve dysfunction, we hypothesized that dexameth-
asone might help to prevent these complications. DEX has
a long duration of action (T1/2 200 minutes and dura-
Table II. Cranial and cervical nerve dysfunctions
Group A
Temporary
Laryngeal 1.2%
Hypoglossal 0.8%
Marginal mandibular 0.7%
Transverse cervical 0.5
Spinal accessory NR
Glossopharyngeal NR
NR, Not recorded.
Table III. Cranial and cervical nerve injuries
Group A Group B P value
Temporary 2.3% 5.7% .006
Permanent 0.9 1.1 .8916
Total 3.2 6.8 .0081tion of action between 36 and 54 hours) and also anti-inflammatory potency 30 times greater than that of corti-
sone.
Because several trials have established the effective-
ness of DEX in improving outcomes in spinal cord injury
patients, we thought it was reasonable to test our hy-
pothesis in carotid endarterectomy-related cranial nerve
injuries.
Furthermore, our hypothesis was supported by re-
search performed at the University of Osaka in 1995.22 In
this study, rats with hypoglossal nerve injuries were treated
with dexamethasone, which enhanced hypoglossal nerve nu-
clear levels of growth-associated protein (GAP)-43messenger
ribonucleic acid (mRNA) and facilitated regeneration. Since
we could not measure the levels of GAP-43 mRNA in our
patients, but were supported by reports of the effectiveness
of this steroid in rats, we designed our study to test the
clinical efficacy of DEX in ameliorating the clinical mani-
festations of operative trauma to the cranial nerves.
Our data reveal a statistically significantly lower inci-
dence of clinically apparent cranial nerve injuries in patients
treated with DEX. The beneficial effects of dexamethasone
were noted only on the incidence of temporary nerve
dysfunction. Dexamethasone treatment had no apparent
effect on the incidence of permanent nerve dysfunction.
This finding suggests that temporary nerve dysfunction
may be caused by trauma-related local inflammation, while
permanent deficits are related to loss of nerve integrity. Our
study design does not permit evaluation of the effect of
DEX on recovery time after nerve injury, since we felt it
important to administer steroids postoperatively to patients
in both groups A and B with postoperative clinical mani-
festations of nerve injury.
A number of complications can result from prolonged
DEX therapy. These include fluid and electrolyte abnor-
malities, hypertension, hyperglycemia, increased suscepti-
bility to infection, osteoporosis, myopathy, behavioral dis-
turbances, cataracts, growth arrest, and the characteristic
Cushing-like habitus of steroid overdose.However, a single
dose, even a large one, is virtually free from harmful effects,
and a short course of therapy (up to 1 week), in the
absence of specific contraindications, is unlikely to be
harmful. If the duration of therapy is increased beyond 1
week, there are time- and dose-related increases in the
incidence of adverse effects.24 In this regard, it should be
Group B
manent Temporary Permanent
0.2 2.8% 0.4
0.2 2.2% 0.1
0.3 1.1% 0.2
0.2 0.7 0.4
NR NR NR
NR NR NRPerpointed out that new strategies targeting multiple pro-
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etanercept or melatonin) are under investigation in exper-
imental murine models of spinal cord trauma, in the at-
tempt to minimize the risk of side effects experienced by
patients treated with high-dose GC therapy. The results are
providing evidence that the combined low-dose therapy
may be effective and also safer than a single effector mole-
cule for the management of SCI.25
In conclusion, our data demonstrate that pre- and
postoperative administration of dexamethasone is effective
in decreasing the incidence of temporary post-carotid end-
arterectomy cranial nerve dysfunction.
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